Key result
Genetic variants in DDAH1 (rs233112 minor allele) and DDAH2 (rs805304 major allele) were significantly associated with higher blood ADMA concentrations, whereas AGXT2 and PRMT1 SNPs were not.
Why the study?
Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthesis and cardiovascular risk factor, but its regulation had been studied less in humans than in experimental models.
Are common single-nucleotide polymorphisms in PRMT1, DDAH1, DDAH2, and AGXT2 genes associated with blood ADMA concentration in humans?
Observational (n=377)
Are common single-nucleotide polymorphisms in PRMT1, DDAH1, DDAH2, and AGXT2 genes associated with blood ADMA concentration in humans?
DDAH1 and DDAH2 are the major enzymes regulating blood ADMA concentration in humans, with specific genetic variants significantly associated with higher ADMA levels.
Supports DDAH1/2 as key ADMA regulators; leaves open whether genotyping aids risk stratification or therapy.
Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthesis and a cardiovascular risk factor. Its regulation has been studied extensively in experimental models, but less in humans. We studied common single-nucleotide polymorphisms (SNPs) in genes encoding for enzymes involved in ADMA biosynthesis and metabolism, i.e., PRMT1, DDAH1, DDAH2, and AGXT2, and assessed their associations with blood ADMA concentration in 377 unselected humans. The minor allele of DDAH1 SNP rs233112 was significantly more frequent in individuals with ADMA in the highest tertile or in the highest quartile, as was the major allele of DDAH2 rs805304. A combined genotype comprising both SNPs showed a significant genotype-phenotype association, with increasing ADMA concentration by an increasing number of inactive alleles. SNPs in the AGXT2 and PRMT1 genes showed no significant associations with blood ADMA concentration. Our study provides comprehensive evidence that DDAH1 and DDAH2 are the major enzymes regulating blood ADMA concentration, whilst PRMT1 indirectly affects ADMA, and AGXT2 may act as a back-up enzyme in ADMA metabolism under pathophysiological conditions only.
No takes yet. Share an insight, caveat, or question.
Hannemann et al. (2022) conducted an observational in Unselected humans (n=377). SNPs in PRMT1, DDAH1, DDAH2, and AGXT2 genes vs. Reference alleles/genotypes was evaluated on Blood ADMA concentration. Genetic variants in DDAH1 (rs233112 minor allele) and DDAH2 (rs805304 major allele) were significantly associated with higher blood ADMA concentrations, whereas AGXT2 and PRMT1 SNPs were not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: